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ABSTRACT
Cancer is genetically heterogeneous regarding to molecular genetic characteristics
and pathogenic pathways. A wide spectrum of biomarkers, including DNA markers,
is used in determining genomic instability, molecular subtype determination and
disease prognosis, and estimating sensitivity to different drugs in clinical practice.
In a previous study, we developed highly effective DNA markers using improved
random amplified polymorphic DNA (RAPD) with high-GC primers, which is a valuable
approach for the genetic authentication of medicinal plants. In this study, we applied
this effective DNA marker technique to generate genetic fingerprints that detect
genomic alterations in human breast cancer tissues and then developed sequencecharacterized amplified region (SCAR) markers. Three SCAR markers (BC10-1, BC134 and BC31-2) had high levels of genomic DNA amplification in breast cancer. The
PHKG2 and RNF40 genes are either overlapping or close to the sequences of SCAR
marker BC13-4, while SCAR marker BC10-1 is in the intron and overlap the DPEP1
gene, suggesting that alterations in the expression of these genes could contribute
to cancer progression. Screening of breast cancer cell lines showed that the mRNA
expression levels for the PHKG2 and DPEP1 were lower in non-tumorigenic mammary
epithelial cell MCF10A, but elevated in other cell lines. The DPEP1 mRNA level in
invasive ductal carcinoma specimens was significantly higher than that of the adjacent
normal tissues in women. Taken together, high-GC RAMP-PCR provides greater
efficacy in measuring genomic DNA amplifications, deletion or copy number variations.
Furthermore, SCAR markers BC10-1 and BC13-4 might be useful diagnostic markers
for breast cancer carcinomas.
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INTRODUCTION

requirements of the amount of template DNA, produces no
hazardous contamination, and is simple and inexpensive, the
few disadvantages that poses including poor reproducibility
and low production or yield. Resolution and production
of RAPD are greatly increased by prolonging the RAMP
time from the stage of annealing to extension in PCR [18,
19]. To improve the effectiveness of the RAPD method, we
developed a highly effective DNA marker technique using
improved RAPD with high-GC content primers, in which
the GC content reaches 8–10 nucleotides for a 10 nucleotide
primer (80~100%) [20,21]. The Sequence Characterized
Amplified Region (SCAR) markers are very stable,
sensitive, and reliable. These markers are also effective for
diagnostic purposes by using a simple PCR assay, which
are generally derived from the molecular cloning of RAPD
fragments in medicinal plants [21–28].
Different types of cancers have been associated
with abnormal DNA fingerprinting; therefore, in this
study we applied this effective improved RAPD technique
to generate genetic fingerprints that detect genomic
alterations in human breast cancer and develop diagnostic
SCAR markers.

Breast cancer (BC) has the highest incidence of
cancer occurrence in the female population and is the
number one cause of cancer deaths for women worldwide
[1–5]. In 2017, there were 252,710 estimated new cases of
BC and 40,610 expected BC deaths among women in the
United States [1]. Resource-stratified guidelines provide a
vehicle for designing programs to promote early detection,
diagnosis, and treatment using existing infrastructure and
renewable resources and methods. Existing strategies for
evaluating the current state and projecting future burden
have a major role in developing new strategies to improve
BC outcomes at the national and international levels
[6–8]. While China’s mainland currently has 470,000
BC patients, only 20 percent of them were diagnosed at
early stage, whereas, in USA, 80 percent of BC patients
were diagnosed at an early stage, securing best practice
and best outcome for the patients (http://www.chinadaily.
com.cn/china/2012–03/12/content_14814002.htm). Thus,
we must increase BC risk awareness in the general public
by recommending regular screening starting at 40 years of
age to promote early detection and treatment.
Cancer is genetically heterogeneous regarding to
molecular characteristics and pathogenic pathways. A wide
spectrum of biomarkers, including DNA markers, is used
for determining genomic instability, molecular subtype
determination, and prognosis, and estimating sensitivity to
different drugs in practice. Systematic analysis of genetic
changes in colon cancer development demonstrated
that multiple mutations are necessary for the evolution
of normal cells into cancer cells [9]. There is growing
evidence that multiple mutations are responsible for the
development of cancer; cancer cells must exhibit mutator
phenotypes [10, 11], which are likely to be responsible for
the genomic instability found in cancer tissues. Mutator
phenotype, including defective mismatch repair, is
known to cause microsatellite instability, associated with
multiple hereditary cancers [12, 13]. Loss of chromosomal
materials would inactivate tumor suppressor genes while
gain of chromosomal materials has the potential to activate
tumor-promoting genes [8]. Genomic instability and
chromosome copy number variations are the hallmarks
of neoplastic transformation and a herald of genomic
damage, leading to the conclusion that multiple mutations
are the driving force in the carcinogenic processes [14–
16]. Thus, the development of diagnostic markers for BC
is vital for early detection and treatment of BC patients.
Since the 1990s, a number of genetic and DNAbased molecular marker techniques have been developed,
including random amplified polymorphic DNA (RAPD)
[17, 18]. Since then, RAPD technique either alone or in
combination with other techniques is widely used for the
genetic characterization of different medicinal plants,
and other organisms [18, 19]. Although RAPD has few
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RESULTS
RAPD amplification from breast tumor tissue
DNA samples using high-GC primers
To increase the efficiency of RAPD amplification
and obtain more specific bands, standard primers were
replaced with high-GC content primers (FY-10, FY-13
and FY-32). In addition, the RAMP time from the stage of
annealing (36ºC) to extension (72ºC) was set to 5% (0.125
ºC/s). This improved RAPD was used to amplify genomic
DNA from five breast cancer patients. For each patient,
two tissue samples were obtained from both the tumor and
the normal tissue adjacent to the tumor. The PCR products
were resolved by electrophoresis on a 1.5% agarose gel
and showed signal difference in intensity of RAPD bands
within patients (Figure 1).

Cloning and sequencing of DNA fragments
Three different bright bands with over-amplification
in Figure 1 were excised and purified from the agarose
gel for cloning into the pGM-T vector (Figure 2A). The
positive cloned DNA fragments, 10-1, 13-4 and 31-2
(Figure 2B–2D) were selected based on insert sizes by
EcoRI digestion matching those of the RAPD fragments in
Figure 1 and Figure 2A and then sequenced by the Sanger
method. Sequence homology was determined using the
online program BLAST (http://www.ncbi.nlm.nih.gov/
BLAST/) against the GenBank database.
Sequencing of the aforementioned three cloned
RAPD fragments from human breast cancer tissue
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revealed that clone 10-1 consisted of 1027 nucleotides is
located in the intron of DPEP1 transcript variant 2, and
overlapped DPEP1 (dipeptidase 1) transcript variant 1 in
GenBank (NM_004413) (Figure 3A and Figure 4A). Clone
13-4 consisted of 663 nucleotides (Figure 3B), located
only 536 bp away from the PHKG2 gene (Homo sapiens
phosphorylase kinase, gamma 2, NM_000294) (Homo
sapiens chromosome 16, GRCh38 Primary Assembly.
Sequence ID: ref|NC_000016.10|Length: 90338345,
Range of clone13-4: 30761532 to 30762194 vs Range of
PHKG2: 30748299 to 30761176) (Data not shown), and is
also mainly located within or overlapping the first exon of
RNF40 (Homo sapiens ring finger protein 40, E3 ubiquitin
protein ligase, NM_014771.3) (Figure 4B and Figure 5)
in GenBank. Clone 31-2 consisted of 1104 nucleotides
that did not match any known genes in GenBank (Figure
3C). Clone 10-1 is mapped to chromosome 16p24.3, clone
13-4 is mapped to chromosome 16p11.2, and clone 31-2 is
mapped to chromosome 11q13.5.

SCAR markers BC10-1 and BC31-2 showed higher signals
indicating that these SCAR markers have genomic DNA
over-amplified in the tumor tissues (Figure 6).
Real-time PCR was performed, including ten
samples of women’s blood DNA, 22 samples of adjacent
normal tissue DNA and 30 samples of breast tumor tissue
DNA. The results of SCAR marker BC10-1 showed
gradually increased levels from blood DNA to tumor
DNA (p-value ≤ 0.05) (Figure 6C). SCAR marker BC134 is present in increased levels in DNA from adjacent
and tumor samples compared to blood DNA (p-value ≤
0.05), but no difference in levels between adjacent DNA
and tumor DNA (Figure 6D). SCAR marker BC31-2 did
not show increased levels between blood DNA and tumor
DNA (data not shown)

DPEP1 mRNA expression in BC cells and
invasive ductal carcinomas
The mRNA expression from the DPEP1 gene
was performed by real-time PCR using RNA extracted
from BC cell lines BT549, MDA-MB-231 and MDAMB-435, and non-tumorigenic mammary epithelial
cell line MCF10A. We found that the level of DPEP1
mRNA expression was lower in non-tumorigenic
cell line MCF10A, but elevated in other BC cell lines
(Figure 7A). To determine the DPEP1 levels in BC
development, we collected invasive ductal carcinoma
specimens from 33 human BC patients and 11 adjacent
normal tissues with informed consent. Total RNAs were
purified from each tumor tissue and the surrounding
normal tissues followed by real-time PCR. Figure 7B
shows that the mRNA levels of DPEP1 in BC tissues
were significantly higher (11.6-fold) than that of the
adjacent normal tissues.

Development of diagnostic SCAR markers
To generate stable diagnostic SCAR markers from
our cloned RAPD fragments, three pairs of primers for
semi-quantitative PCR (Table 3) and three pairs of primers
for real-time PCR (Table 4) were designed and synthesized
based on the cloned sequences. The semi-quantitative
SCAR primer pairs were used to amplify ten samples of
genomic DNA collected from the breast tumors of five
breast cancer patients. Genomic DNA from non-tumor
adjacent tissue was used to test for amplification markerspecificity and to verify that the genomic DNA was overamplified in the tumor. The PCR results indicated that the
products with expected size were observed in all samples by
three SCAR markers (Figure 6A, 6B, and data not shown).

Figure 1: Improved RAPD PCR from breast cancer tissues and their adjacent tissues. (A) High-GC primer FY-10. (B) High-

GC primer FY-13. (C) High -GC primer FY-31. Five pairs of genomic DNA from breast cancer tissues and their adjacent or surrounding
normal tissues were subjected to improved RAPD amplification (high-GC RAMP-PCR). Lanes 1, 3, 5, 7 and 9 are DNA from breast cancer
tissues (see Table 1). Lanes 2, 4, 6, 8 and 10 are their matched DNA from adjacent tissue. The blue arrows indicate bands that were excised
for DNA cloning. Lane “M” shows the DL2000 DNA molecular weight marker (bp).
www.impactjournals.com/oncotarget
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Figure 2: Molecular cloning for RAPD products. (A) Agarose gel electrophoresis for RAPD DNA fragments 10, 13 and 31 derived

from high-GC primers FY-10, FY-13 and FY-31, respectively. “T” indicates “pGM-T vector”. (B) Enzymatic identification of positive clones
from RAPD fragment 10. (C) Enzymatic identification of positive clones from RAPD fragment 13. (D) Enzymatic identification of positive
clones from RAPD fragment 31. Lane 1 contains undigested plasmid DNA; lane 2 contains plasmid DNA after EcoRI digestion. Clones 10-1,
13-4 and 31-2 (blue text color) were selected for Sanger sequencing. Lane “M” contains the DL2000 DNA molecular weight marker (bp).

Figure 3: Results of Sanger-sequencing of the cloned DNA fragments. (A) The sequence of clone 10-1. (B) The sequence of
clone 13-4. (C) The sequences of clone 31-2.
www.impactjournals.com/oncotarget
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PHKG2 mRNA expression in BC cells

to improve the effectiveness of the RAPD method (highGC RAMP-PCR technique) [20]. This improved RAPD
successfully increased the number of RAPD bands
produced from a given DNA sample. Using improved
RAPD with high-GC content primers, we found that the
average number of bands per primer increased from 6.41
to 15.04 in comparison to regular RAPD with standard
primers. The average number of polymorphisms per
primer was also increased from 4.647 to 10.22 [20].
Thus, we can produce more polymorphic bands using
less RAPD primers. With these successes, we decided
to apply this simple yet effective improved RAPD
technique with high-GC primers to generate more
fingerprints for detecting genomic alterations in human
BC and developing diagnostic SCAR markers. High-GC
primers FY-10, FY-13 and FY-32 were used to amplify
genomic DNA successfully from five pairs of BC tissues
and their adjacent tissues. Three different over-amplified
bands were purified from the agarose gel, cloned and
sequenced, and then used to successfully generate stable
diagnostic SCAR markers BC10-1, BC13-4 and BC31-2.
Real-time PCR was performed using DNAs from
bloods, tumor tissues and normal tissue adjacent to the
tumor. SCAR marker BC10-1 results showed gradually
increased levels from blood DNA to tumor DNA. SCAR
marker BC13-4 are shown to have increased levels in both
tumor tissues and normal tissues adjacent to the tumors
compared to DNA from blood; however, there was no
difference between DNA from tumor samples and adjacent
tissues. SCAR marker BC31-2 did not show increased
levels of tumor DNA compared to blood DNA. These
results indicate that SCAR markers BC10-1 and BC13-4

The mRNA expression from the PHKG2 gene was
performed by real-time PCR using RNA extracted from
breast cancer cell lines; we found that the level of PHKG2
mRNA expression was lowest in the non-tumorigenic
cell line MCF10A, but elevated in the other BC cell lines
(Figure 7C).

DISCUSSION
The RAPD technique either alone or in
combination with other technique is widely used
for the genetic characterization of different plants,
animals or other organisms, particularly in medicinal
plants [17–19]. In a recent cancer study, RAPD was
also used for screening genome-wide changes in DNA
methylation, which was called Methylation SensitiveRandom Amplified Polymorphic DNA-Polymerase
Chain Reaction (MS-RAPD-PCR) [29]. Cancer patients
are predisposed to fungal infections caused by Candida
albicans, especially oral or respiratory tract candidiasis.
Biernasiuk and colleagues [30] applied RAPD-PCR to
successfully estimate genetic diversity of C. albicans
isolated from the upper respiratory tract of patients
with non-small cell lung cancer. However, there are
some disadvantages to RAPD, like poor reproducibility
and low yield of PCR products (low production).
The resolution and production of RAPD are greatly
increased by prolonging the RAMP time from the stage
of annealing to extension in PCR [18, 19]. Recently, the
technique was modified using high-GC content primers

Figure 4: The Human genome locations of clones 10-1 and 13-4 with their partial cDNAs of DEPEP1 and RNF40,
respectively.
www.impactjournals.com/oncotarget
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Figure 5: The sequence of clone 13-4 aligns with RNF40 cDNA. Depicted is the BLAST output showing alignment of the clone
13-4 and RNF40 cDNA sequences. The sequence of clone 13-4 showed 583bp (Plus strand) identity with the cDNA of RNF40 (minus strand).
www.impactjournals.com/oncotarget
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could be useful diagnostic markers of genomic instability
or chromosome copy number variation in BC [14–16].
To note, the PHKG2 (Phosphorylase Kinase
Subunit Gamma-2) gene, which encodes a subunit of
phosphorylase kinase (Phk), is located close to SCAR
marker BC13-4. Heritable deficiency of Phk, a regulatory
enzyme of glycogen metabolism, is responsible for 25%
of all cases of glycogen storage disease and occurs in 1
in 100,000 births. Liver phosphorylase b kinase (PhK)
deficiency (glycogen storage disease type IX), one of
the most common causes of glycogen storage disease, is
brought by mutations in the PHKA2, PHKB and PHKG2
genes. Mutations in the testis/liver isoform of PHKG2,

which leads to approximately 10–15% of cases, have
been associated with autosomal liver glycogenosis in gsd
rats and humans [31–33]. However, the role of PHKG2 in
BC is unknown. Real-time PCR indicated that the level of
mRNA expression for the PHKG2 gene was lowest in nontumorigenic BC cell line MCF10A, compared to elevated
levels in all other tumorigenic BC cells tested. Of course,
the levels of protein should be tested to further confirm
their significance. Clone 10-1 was located and shown to
overlap with DPEP1 gene which promoted metastasis in
colon cancer [34–36] but inhibited tumor cell invasiveness
in pancreatic ductal adenocarcinoma [37]. The role of
DPEP1 in different types of cancer is controversial

Figure 6: Genomic DNA amplification of SCAR markers BC10-1, BC13-4 and BC31-2 in breast cancer patients. (A)

SCAR marker BC10-1 in five pairs of genomic DNA from breast cancer tissues and their adjacent tissues. (B) SCAR marker BC31-2 in
five pairs of genomic DNA from breast cancer tissues and their adjacent tissues. Lanes 1, 3, 5, 7 and 9 contain DNA from breast cancer
tissues (see Table 1). Lanes 2, 4, 6, 8 and 10 contain their matched adjacent tissue DNA. Blue arrows indicate the amplified band, whereas
the stars “*” indicate the internal control. (C) Real-time PCR for SCAR marker BC10-1. (D) Real-time PCR for SCAR marker BC13-4.
“Cancer”, breast cancer tissues; “Adjacent”, normal tissues adjacent to or surrounding the breast tumor; “Ctrl”, normal women blood DNA;
“**”p value ≤ 0.05.
www.impactjournals.com/oncotarget
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[34–38]. Our results, for the first time, showed that the
mRNA levels of DPEP1 in BC tissues were significantly
higher (11.6-fold) than that of the adjacent normal tissues,
which may play a role in promoting BC metastasis and
invasiveness. Taken together, the DPEP1 and PHKG2
gene may be prognostic targets, which would play a vital
role in BC carcinogenesis. Further studies of how the
DPEP1, PHKG2 and RNF40 function in BC progression
and how they might be used for risk prediction and therapy
are underway.

at Southwest Medical University Affiliated Hospital in
China with informed consent [39–42]. The protocol for
human samples was approved by the Ethics Committee
of Southwest Medical University. The patients were
Chinese women, between 26 to 68 years old and did
not receive preoperative radiotherapy or chemotherapy.
The histopathologic profiles of the 5 breast carcinomas
specimens for RAPD amplification are shown in Table 1.
The cancer tissues and adjacent tissues or surrounding
normal tissues were immediately frozen in liquid nitrogen
and stored at −80ºC. DNA extraction from tissues was
performed using the Proteinase K and phenol/chloroform
method [40, 43–45]. Total RNA was isolated from cancer
cells and tissues using the RNeasy Mini Kit (50) (Cat
No.74104, QIAGEN) and stored at −80ºC. The RNA
and DNA quality was determined by a 1% agarose gel
electrophoresis and spectrophotometry. Genomic DNA

MATERIALS AND METHODS
Breast carcinoma DNA and RNA preparation
Human breast invasive ductal carcinoma specimens
were collected from surgically removed tumor tissues

Figure 7: Analysis of DPEP1 and PHKG2 expression in breast cancer cell lines and tissues. (A) DPEP1 gene expression in

breast cancer cell lines. (B) DPEP1 gene expression in invasive ductal carcinoma specimens. (C) PHKG2 gene expression in breast cancer
cell lines. “MDA231”, MDA-MB-231 cells; “MDA435”, MDA-MB-435 cells.
www.impactjournals.com/oncotarget
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Table 1: The histopathologic profiles of the 5 breast carcinomas specimens
Histology
Diagnostic age
Stage
Grade
Estrogen receptor
Progesterone receptor
HER-2
E-Cadherin
p53
Ki-67

1 (TG53)

3 (TG55)

5 (TG57)

7 (TG59)

9 (TG62)

Ductal
49
T3
II
+,90%
+,10%
1+
+
−
+, 40%

Ductal
38
T4
III
−
−
1+
+
+, 90%
+, 75%

Ductal
68
T2
II
−
−
0
+
+, 40%
+, 70%

Ductal
45
T2
III
−
−
3+
+
+, 30%
+, 15%

Ductal
48
T3
III
−
−
0
+
+, 60%
+, 50%

Molecular cloning of RAPD fragments from
amplification by high-GC primers

from healthy women was also isolated from peripheral
leukocytes or blood using the previously described method
[43]. The final concentration of all DNA samples was
adjusted to 20 ng/μl and stored at −20 ºC until use.

Cloning of RAPD fragments was described
previously [21, 23, 27, 28, 44]. Bands with differential
amplification were excised from agarose gels and purified
with a TIANgel Mini Purification Kit (DP209, China)
according to the company provided protocol. Purified
DNA fragments were ligated into pGM-T vector (VT202,
Tiangen reagents, Beijing, China), and transformed into
DH5α E. coli complement cells. The recombinant clones
were selected on LB agar plates from blue and white
colonies. The presence of right insert was verified by PCR
by using T7/SP6 primer pairs, and EcoRI digestion from
purified plasmids. The positive clones were selected for
Sanger sequencing.

High-GC primers for RAPD
The 10-bp length oligos with high-GC contents (90%
of G+C) were designed and synthesized at Beijing DNA
chem. Biotechnology Co., Ltd (Beijing, China) and were
as previously described [20]. The sequences of high-GC
primers FY-10, FY-13 and FY-31 are presented in Table 2.

Amplification of DNA by high-GC RAPD PCR
All the contents of the PCR (10 μl total) were
as follows: 1 μl of 2.5 μmol/L primers, 0.5 μl of DNA
template (10 ng), 5 μl of 2×PCR Taq MasterMix (TianGen
Biotech Co. Ltd., Beijing, China), 3.5 μl of deionized
water. PCR conditions were as follows: initial denaturation
at 95ºC for 90 s, followed by 40 cycles of 40 s at 94ºC,
60 s at 36ºC, 90 s at 72 ºC, and final extension of 5 min
at 72ºC. PCR amplification was executed in an “Applied
Biosystems Veriti® 96-Well Thermal Cycler” (Life
Technology, USA), and the RAMP time from annealing
to extension with a RAMP rate for 5% (0.125 ºC/s) was
used [20, 21].

Development of diagnostic SCAR markers
Homology searches within the human genome were
performed using BLAST (http://www.ncbi.nlm.nih.gov/
BLAST/). The sequence of each cloned RAPD fragment
was used to design pairs of SCAR primers using Primer
3 software (http://frodo.wi.mit.edu/primer3). Sequences
of the SCAR primers, amplification length and PCR
conditions are shown in Table 3. Ten DNA samples,
which we mentioned previously, were used as templates
for PCR amplification for development of SCAR markers.
The PCR reaction solution consisted of 5 μl 2×Taq PCR
MasterMix, 1 μl of 2.5 μM each pair of SCAR primers and
1 μl of genomic DNA (20ng), with a total volume of 10μl.
Amplification reactions were performed with an initial
pre-denaturation of 90 s at 95°C followed by 33 cycles
of denaturation at 94°C for 40 s, annealing at 60°C for
30 s, and extension at 72°C for 30 s. The final extension
step was performed at 72°C for 5 min. The amplified
PCR products were resolved by electrophoresis on a 1.5%
agarose gel [19, 43]. For semi-quantitative genomic DNA
PCR using SCAR markers, GAPDH gene served as a
loading control.

Agarose gel electrophoresis
The amplified RAPD-PCR products were resolved
by electrophoresis on a 1.5% agarose gel in 1× TAE (Trisacetate-EDTA) buffer at 60 volts for 210 minutes at 4 ºC.
To increase the resolution, the electrophoresis time was
extended to 240 minutes at 60 volts at 4 ºC. Then, the
gels were visualized by 0.5 μg/mL ethidium bromide
(EB) staining, and the images were documented using
the ChemiDoc XR (Bio-Rad, USA) [19, 43]. Bands
with different intensity between BC tumors and adjacent
normal tissues were selected for cloning.
www.impactjournals.com/oncotarget
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Table 2: The sequences of high-GC primers
Name

Sequence (5′-3′)
GCTCCCGCCG
GCGTCCCGCC
CGTGGCCCCG

FY-10
FY-13
FY-31

Table 3: Sequences of SCAR primers, PCR product size (bp)
SCAR

5′-primer

Sequence (5′-3′)

3′-primer

Sequence (5′-3′)

Size

Tm (°C)

BC10-1

BC10-1L

GATCACAGGCAGTCAGAGAGG

BC10-1R

CAGGCCACTTGAGACTCTCTG

590

60

BC31-2

BC31-2L

ACAAACGGCCCCATTTCTTTG

BC31-2R

TTGGTGGTTGTGGTAGATGGG

512

60

ACCCAGAAGACTGTGGATGG

GAPDH3G

TGACAAAGTGGTCGTTGAGG

376

60

GAPDH GAPDH5G

Note: SACR, sequence-characterized amplified region; bp, base pair.

Table 4: Sequences of real time PCR primers for SACR markers, probes
SCAR
BC10-1
BC13-4
beta-actin

5′-primer

Sequence (5′-3′)

3′-primer

Sequence (5′-3′)

Probe

BC10-1L87
BC13-4L34
Q-b-actin55LG

cccaggcagtagtgtagggta
tctggcttcttcccaaacac
aagtcccttgccatcctaaaa

BC10-1R87
BC13-4R34
Q-b-actin55RG

ccctcctctccatttctcaa
cgcggtgtcagttactatgg
atgctatcacctcccctgtg

87
34
55

Note: SACR, sequence-characterized amplified region.

Table 5: Sequences of real time PCR primers for PHKG2 and DPEP1 mRNA expression, probes
5′-primer

Sequence (5′-3′)

3′-primer

Sequence (5′-3′)

Probe

PHKG2

Gene

Q-PHKG2-L2

caatatgcagatccgactttca

Q-PHKG2-R2

ggggtcccacacaactctc

2

DPEP1

Q-DPEP1-13L

tgcactgcagacttctttcg

Q-DPEP1-13R

gccaggggaggtcattgt

13

18S48R

gcaattattccccatgaacg

18S48L

gggacttaatcaacgcaagc

48

18S

Quantitative real-time PCR amplification

USA). The method for real-time PCR was described
previously [41, 42, 46–48]. Sequences of the primers and
probes for human PHKG2 and DPEP1 mRNA are shown
in Table 5. Levels of the 18S rRNA were measured in
the same reaction for each sample to serve as an internal
control for normalizing the relative mRNA levels of
PHKG2 and DPEP1.

Three pairs of primers for real-time PCR of SCAR
markers and β-actin were designed using software from
assay design center of Roch (http://lifescience.roche.com/
shop/CategoryDisplay?catalogId=10001&tab=&identifier
=Universal+Probe+Library). Sequences of real-time PCR
primers and probes for genomic DNA are shown in Table 4.
Real-time PCR was performed using the FastStartUniversal
Probe Master (Rox) (Cat No. 4914058001, Roch) and the
StepOnePlus Real-Time PCR system (Applied Biosystems,
USA) as described previously [39, 41, 42, 46–48]. The
β-actin gene served as an internal control for normalizing
the relative levels of SCAR markers.

Statistical analysis
Student’s t-test was used to determine any significant
differences. A p-value of less than 0.05 was considered
to be significant for all tests. All the experiments were
repeated thrice.
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